Compare EPC & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPC | SDGR |
|---|---|---|
| Founded | 1999 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2000 | 2020 |
| Metric | EPC | SDGR |
|---|---|---|
| Price | $16.73 | $17.64 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 7 |
| Target Price | $23.17 | ★ $26.57 |
| AVG Volume (30 Days) | 852.4K | ★ 915.0K |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | ★ 3.55% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | ★ $2,223,500,000.00 | $256,951,000.00 |
| Revenue This Year | $2.81 | $23.69 |
| Revenue Next Year | $1.66 | $20.46 |
| P/E Ratio | $31.91 | ★ N/A |
| Revenue Growth | N/A | ★ 32.90 |
| 52 Week Low | $16.63 | $15.99 |
| 52 Week High | $38.45 | $28.47 |
| Indicator | EPC | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 35.06 | 46.04 |
| Support Level | $16.65 | $16.86 |
| Resistance Level | $17.67 | $18.42 |
| Average True Range (ATR) | 0.61 | 0.70 |
| MACD | 0.00 | 0.19 |
| Stochastic Oscillator | 5.97 | 67.49 |
Edgewell Personal Care Co is a personal-care company. The operating segments of the company include Wet Shave, Sun and Skin Care and Feminine Care. Some of the brands offered by the company include Edge, Skintimate, Personna, Schick, Carefree, Playtex, Banana Boat and Hawaiian Tropic. It derives a majority of its revenue from the United States.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.